Background: Chemotherapy-induced diarrhea (CID) is a common side effect of a number of chemotherapeutic agents. Conventional therapy for severe CID with opioids or loperamide is moderately effective. A prospective trial was conducted using octreotide acetate for treatment of severe CID refractory to loperamide.
Introduction
Chemotherapy induced diarrhea (CID) is a major side effect of some chemotherapeutic agents. Severe diarrhea can be a life threatening disorder if not treated immediately and leads to discontinuation of treatment [1, 2] . The incidence of diarrhea in patients with colorectal carcinoma treated with 5-fluorouracil (5-FU) and leucovorin is about 25% [3, 4] . Diarrhea is the main toxicity in patients treated with irinotecan (CPT-11) [5] . The risk of CID is significantly higher for regimens that contain fluoropyrimidines and CPT-11. The incidence of diarrhea associated with 5-FU and CPT-11 has been reported to be as high as 50%-80% [6, 7] .
The etiology of CID is not completely understood. In the majority of patients, diarrhea resolves spontaneously or by treatment with diphenoxylate atropine or loperamide [8] . Some patients remain refractory to this treatment and need hospitalization for treatment with bowel rest (nothing by mouth) and intravenous fluid hydration. Octreotide was used by Cascinu et al. for control of CID in patients receiving 5-FU [9] . In their study, diarrhea resolved in 26 of 27 patients. Others also reported similar results using octreotide in the treatment of CID [10] . Although this agent has been effective against CID, no widely used guidelines for its use are accepted. We performed a prospective study to evaluate the efficacy and toxicity of octreotide acetate for treatment of refractory CID (grade 2-3) in salvage setting.
Patients and methods
Thirty-two patients were treated with octreotide for CID in two cancer centers IRB approval was obtained and each patient signed an informed consent form prior to treatment. All had grade 2 (4-6 stools daily) or grade 3 (7-9 stools daily) CID according to WHO toxicity criteria, as a result of chemotherapy with 5-FU containing combinations. Patients started treatment either while hospitalized or as outpatients in the daycare unit on the first day, continuing treatment at home. All 32 patients failed a 48-hour treatment with loperamide before starling octreotide.
Chemotherapeutic regimens were as follows: Thirteen patients with colorectal cancer Dukes C2 received adjuvant chemotherapy with 5-FU and leucovonn Six of ten patients with metastatic colorectal cancer received the same regimen, and four received CPT-11 with leucovorin and 5-FU. Three patients with gastric cancer, two with pancreatic cancer, two with breast cancer and one with laryngeal cancer received 5-FU based combinations including one or more of the following: cyclophosphamide, epirubicin, cisplatin and methotrexate. One ovarian cancer patient received cyclophosphamide and cisplatin followed by radiotherapy to the pelvis.
No patients (with the exception of one patient with ovarian cancer) had received radiation therapy. No history of diarrhea before starting chemotherapy was documented. Patients had white blood cell count > 2500/ul and normal liver and renal function tests and negative stool culture. Octreotide was administered by subcutaneous injection 100 ug 3x/day for three days followed by 50 ug 3x/day for an additional Days of therapy Number of patients responding " Grade 2. 4-6 stools/day: grade 3-7-9 stools/day. three days. Response to treatment was assessed as follows: complete response = complete resolution of diarrhea; partial response = one to two diarrheas daily; no response = three or more diarrheas daily; progression: increased number of diarrheas.
Results
Thirty-two patients, twenty-one male and eleven female, were treated with octreotide. Median age was 56 years and performance status (WHO criteria) was 1-3 (Table 1) . Eighteen patients had grade 3 and fourteen had grade 2 diarrhea. Fourteen patients developed diarrhea after the first cycle of chemotherapy, ten after two cycles and eight after three or more cycles. The single patient with ovarian cancer received also radiation therapy to the pelvis two year prior to treatment with octreotide and had suffered since that time from grade 2 diarrhea. The median time between chemotherapy and starting octreotide in the other 31 patients was 8 days (range 5-9 days). Median duration of diarrhea before loperamide treatment was 36 hours followed by loperamide (4 mg) given orally and continued by 2 mg every 6 hours for 2 days. Complete resolution of diarrhea was seen within the first day of octreotide therapy in 5 cases, within the second day in 14 cases and within 72 hours in 11 cases (94% CR) ( Table 2 ). The total number of patients treated on outpatient basis was 19. Twelve in complete response stopped octreotide after three days of treatment because they felt very healthy. The remaining 13 were hospitalized for treatment with octreotide (7 of them also received a fluid infusion) and continued treatment as outpatients after improvement. Median duration of hospitalization in this group was 3 days (range 1-7 days). The two hospitalized patients who did not respond to octreotide after three days were treated with bowel rest and intravenous fluid hydration with octreotide (150 ug/hour x 4 per day for 72 hours) then continued with loperamide orally until constipation. No side effects were observed.
Discussion
Clinical and preclinical studies indicate that CID is most likely a multifactorial process that resulting in an imbalance between absorption and secretion in the small bowel [1] . Histopathologic studies have shown that certain chemotherapeutic agents produce acute damage to the intestinal mucosa including loss of intestinal epithelium, superficial necrosis, and inflammation of the bowel wall leading to diarrhea [11, 12] .
Traditional pharmacologic management of CID has included nonspecific agents such as the opium preparation paragoric, opioids diphenoxylate and loperamide. Bismuth subsalicylate has been used to control inflammatory diarrhea caused by radiation and ulcerative colitis [13] . The somatostatin analogue octreotide acetate is a specific antidiarrheal agent which inhibits such gut hormones such as seratonin, vasoactive intestinal polypeptide, gastrin, insulin, glucagon, growth hormone, secretin, motilin, and pancreatic polypeptide that may cause diarrhea [14] . Octreotide also regulates intestinal water and electrolyte transport, primarily inducing net water and electrolyte movement to absorption [15] . In a randomized trial, octreotide given subcutaneously (100 ug x 2 daily for 3 days) compared with loperamide in patients with grade 2 and 3 CID was more effective in the control of diarrhea (90% vs. 15%) [16] . Other studies showed similar results [17] .
Octerotide usually has a rapid effect on CID (i.e., < 2 days) when given as first-line treatment [17, 18] . There is insufficient data concerning this effect when it is given as second line treatment in CID, refractory to loperamide. In the current study, 30 of 32 patients had complete response. In all responders, diarrhea resolved within 72 hours of treatment; in most patients (19 of 32) within the first 48 hours of treatment with octreotide. Patients with grade 4 diarrhea (> 10 stools/day or bloody diarrhea) were not included in this study because such cases are uncommon and require immediate hospitalization, intra-venous hydration, replenishment of electrolytes and i.v. octreotide. No correlation between response rate and gender, age, primary tumor site and primary chemotherapy was observed. Although it is known that there is a pathophysiolgic difference between CPT-11 induced diarrhea compared with 5-FU, three of four patients with metastatic colorectal cancer treated with 5-FU and CPT-11 achieved complete response. The treatment schedule used in this study was chosen because of the short half life of octreotide, safety and high response of this schedule reported in the literature [18, 19] . No toxic side effects were documented.
Our results demonstrated octreotide to be highly effective also when given as second-line therapy in patients with CID. An improvement in the quality of life was documented in all patients. The observation that 12 patients discontinued treatment after 3 days without recurrence of diarrhea suggests that an initial course of treatment with octreotide for 3 days may well be sufficient, with an option for additional medication if necessary. The wide use of fluoropyrimidines and CPT-11 in the treatment of cancer makes the successful treatment of CID an important issue since these drugs have a high risk for CID.
In conclusion, octreotide is a valuable choice in the treatment of advanced grade CID. It can be considered for patients with diarrhea as primary therapy or as second-line therapy after failure of loperamide therapy, and can be given subcutaneously in an initial dose of 100 Mg 3 x daily for two to three days on an out-patient basis with minimal side effects and high response rate.
